Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01108770 · ClinicalTrials.gov registry record

Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia

A clinical trial, sponsored by Edimer Pharmaceuticals.

Completed
Registry status
62
Enrollment target

NCT01108770: Completed study, sponsored by Edimer Pharmaceuticals.

NCT01108770 is a clinical trial that has completed, run by Edimer Pharmaceuticals. The registered enrollment target is 62 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01108770 has completed, sponsored by Edimer Pharmaceuticals.

COMPLETED
Registry status
62 participants
Enrollment target

Study Summary

To characterize skin properties in male subjects with HED

Primary Outcome

The primary objective of this descriptive study is to use skin assessment techniques to characterize skin properties in male subjects affected by HED compared with healthy controls including determination of the number of sweat glands and the rate of sweating.

Trial Details

FieldValue
Enrollment Target 62 participants
Start Date 2010-07
Est. Completion 2010-10
Edimer Pharmaceuticals

11 total trials

What the finished NCT01108770 record still lists

NCT01108770 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 62 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT01108770 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01108770 about?

NCT01108770 is a clinical study titled "Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia". To characterize skin properties in male subjects with HED

What is the current status of trial NCT01108770?

This trial is currently completed. The enrollment target is 62 participants. The study started on 2010-07. Estimated completion is 2010-10.

Who is sponsoring clinical trial NCT01108770?

This trial is sponsored by Edimer Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03231150 · 62 participants · NA

    Plantar Fasciitis Randomized Clinical Control Trial

  • NCT03458676 · 62 participants · NA

    Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies

  • NCT03596086 · 62 participants · Phase 1

    HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM

  • NCT03603405 · 62 participants · Phase 1

    HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01108770, the US trial registry maintained by the National Library of Medicine. NCT01108770 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.